AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02521389
Drug: PWT-143
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
Trial: NCT03531320
Drug: D07001-softgel capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Ingredient:Gemcitabine hydrochloride
Trial: NCT03246282
Drug: Normal Saline 0.9% Infusion Solution Bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml of 0.9% Sodium Chloride Solution
Trial: NCT02362048
Drug: ACP-196
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01267604
Drug: Recombinant FSH (rFSH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225IU
Trial: NCT03515213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01457924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01295450
Drug: Apevinat BC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily.
Trial: NCT01295450
Drug: Vitamin Complex
RxNorm normalized name: Sunmark B Super Vitamin Complex Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
Trial: NCT03167307
Drug: Placebo oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
Trial: NCT00262587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled sugar powder in a placebo inhaler
Trial: NCT00097331
Drug: SB683699
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00316082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
Trial: NCT02044185
Drug: salvage chemotherapy, total body irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: there are no direct interventions to our patients.
Trial: NCT02767674
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 400 mg/m2 IVD d1
Trial: NCT03061565
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
Trial: NCT01751555
Drug: Regimen:TDF+3TC+EFV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF+3TC+EFV for HIV/HBV co-infection
Trial: NCT00975312
Drug: Triple combination cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
Trial: NCT00975312
Drug: Tretinoin 0.05%
RxNorm normalized name: TRETINOIN 0.05% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
Trial: NCT01922492
Drug: Oral anti-diabetic drugs
RxNorm normalized name: Diabetic Tussin EX Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.~* Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose.
Trial: NCT04305197
Drug: ICP-022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Trial: NCT01356355
Drug: Herbmed plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
Trial: NCT01356355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule twice a day daily till ureteral stent in situ
Trial: NCT03580889
Drug: Normal Saline Flush, 0.9% Injectable Solution
RxNorm normalized name: Normal Saline Flush, 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between Normal saline, atropine and glycopyrrolate
Trial: NCT04305197
Drug: ICP-022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Trial: NCT02388802
Drug: Immunosuppressive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
Trial: NCT00696410
Drug: Zinc Acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels \~10-12.
Trial: NCT03275025
Drug: YRA-1909 mid dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A mid dose of YRA-1909; daily oral intake for 12 weeks
Trial: NCT03275025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo dosing with daily oral intake for 12 weeks
Trial: NCT04305197
Drug: ICP-022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Trial: NCT04322123
Drug: Hydroxychloroquine + azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day
Trial: NCT03055143
Drug: Ref-08-038
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/ml intravenous infusion
Trial: NCT00696384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
Trial: NCT02219984
Drug: Anticoagulants
RxNorm normalized name: ANTICOAGULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04639674
Drug: AST-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If no other medicines are taken usually, take AST-120 one hour after each meal with a frequency of three doses a day and one dose every administration. The drug will be taken for four weeks.
Trial: NCT00356954
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04305197
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
Trial: NCT04295005
Drug: DPP-4i
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: film coated tablets, specifically Sitagliptin
Trial: NCT03139422
Drug: Calcium Dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT03110341
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
Trial: NCT02057874
Drug: Magnevist® (Intravenous (IV) administration of MRI contrast agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
Trial: NCT02352597
Drug: phytoestrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg of cimifuga racemosa from day 1- 12
Trial: NCT02243280
Drug: ABT-493
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02243280
Drug: ABT-530
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02539303
Drug: Yamani-15/5 chemical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 20 ml of Yamani-15/5 will be directly infused into the diseased (calcific) arterial distribution.
Trial: NCT01708616
Drug: RO5285119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses
Trial: NCT01708616
Drug: RO5285119 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses
Trial: NCT01847768
Drug: Methacholine Inhalation Challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
Trial: NCT02980692
Drug: SUNPG1623 II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT02980692
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT04497792
Drug: hypoglycemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypoglycemic therapy.
Trial: NCT00306033
Drug: Intravenous ImmuneGlobulin
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03040765
Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj
RxNorm normalized name: ZOLEDRONIC ACID 5MG/BAG 100ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
Trial: NCT03748290
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet
Trial: NCT04237805
Drug: SAF-189s
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg，40mg，80mg，120mg，160mg，210mg，once daily
Trial: NCT01320007
Drug: Preset increase in frusemide dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients in Group 1 will have the Optivol function and alerts switched on. Optivol levels will be downloaded monthly via the Medtronic Carelink Network (for those patients who have it) or during pacemaker follow up appointments.~If the Optivol alarm goes off, all patients will be requested to contact a member of the research team by phone and those with rising Optivol (irrespective of the presence or absence of heart failure symptoms) will be requested to increase the dose of diuretic that they are on by 50% for 1 week then revert to their usual dose after 7 days. A routine renal function check will be performed at the end of the week.
Trial: NCT01532128
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg BIA 9-1067 (single-dose)
Trial: NCT02872701
Drug: OTL38 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Trial: NCT04102202
Drug: BOL-DP-o-05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOL-DP-o-05
Trial: NCT04102202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03483987
Drug: Sof+Ledi+R arm
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
Trial: NCT03483987
Drug: Sof+Dacla+R arm
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
Trial: NCT03483987
Drug: Sof+Velpa+R arm
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses
Trial: NCT03487406
Drug: Placebo Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
Trial: NCT03659448
Drug: SGM-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.
Trial: NCT00612989
Drug: Temodar and O6-Benzylguanine
RxNorm normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG \& then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle \& every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar \& continue fasting 2 hrs after administration of each Temodar dose.
Trial: NCT02284230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02230956
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (placebo) injection into the intra-articular space of the study knee.
Trial: NCT01501669
Drug: Irinotecan, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks~+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks
Trial: NCT00003260
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003260
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003260
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003260
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00288483
Drug: Policosanol
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04535947
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 8 weeks (56 days). Both eyes will be treated.
Trial: NCT01673906
Drug: Diagnostic work up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve a pre-operative cytologic diagnosis of any primary lesion by EUS-FNA. All diagnostic tests (MDCT, PET, EUS) should be performed during a two month time span, in this fixed order. The nuclear medicine doctor will be blinded of findings of MDCT. The gastroenterologist will be blinded about the findings of MDCT and PET until he has completed the diagnostic EUS. For ethical reasons, the findings of MDCT and PET will be disclosed to her/him, while the patient is still sedated in the operating room, just before the FNA. The minimal technical requirement for the techniques, the requested levels of clinical competence of the operators and the procedure for critical revision of radiological and cytological and histological specimens are detailed in the protocol. For PET any 68Ga -labeled-octreotide analogue will be allowed. Before EUS, an extended-esophagogastroduodenoscopy (until the Treitz) until will be performed.
Trial: NCT02255357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution containing only the excipients of the original solution without Oxytocin.
Trial: NCT00763958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match buprenorphine administered for 3 months
Trial: NCT01535820
Drug: Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.
Trial: NCT01535820
Drug: Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
Trial: NCT02240433
Drug: LY2157299
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2157299 administered orally
Trial: NCT01290406
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00777374
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epicutanoeus application of a placebo patch
Trial: NCT00135005
Drug: AMN107, STI571
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02355743
Drug: rtPA lock therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion.
Trial: NCT03984370
Drug: ZP4207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal SC administration
Trial: NCT03701984
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
Trial: NCT00353587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBX-102 Placebo once daily for 16 weeks
Trial: NCT00881179
Drug: Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01552590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00734630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
Trial: NCT02609165
Drug: rhNGF 180 µg/ml eye drops solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eye drops
Trial: NCT01032655
Drug: susceptibility test guided sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid~plus either one of the following~1. Klaricid, 500 mg, bid~2. Cravit, 250 mg, bid~3. Tetracycline, 500 mg, bid
Trial: NCT01258634
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Chemotherapy Courses 1 and 3: 75mg/m2; IV push day 1 Courses 2 and 4: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Good Responders Course 1: 75mg/m2; IV push day 1 Course 2: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Poor Responders Course 2: 75mg/m2; IV push day 1 Course 4: 75mg/m2; IV push day 1, hour 0
Trial: NCT02711904
Drug: Extubation U
RxNorm normalized name: ADAPTER,INTUBATION CAREFUSION #1820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:~* 20 years old - 6.0 mcg/Kg/h~* 30 years old - 5.7 mcg/Kg/h~* 40 years old - 5.3 mcg/kg/h~* 50 years old - 5.0 mcg/kg/h~* 60 years old - 4.6 mcg/kg/h~* 70 years old - 4.3 mcg/kg/h~* 80 years old - 4.0 mcg kg/h.
Trial: NCT01258634
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postoperative Chemotherapy for Poor Responders Courses 1 and 3: 15 mg/m2/dose IV or PO every 6 hours, beginning 24 hours after start of methotrexate infusion and continuing until methotrexate level is \<0.1 uM
Trial: NCT00328432
Drug: celecoxib 400 mg bid
RxNorm normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00944047
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 MG/M2 every two weeks for a total of 4 cycles
Trial: NCT00944047
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)
Trial: NCT01201057
Drug: 0.5% SPL7013 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gel
Trial: NCT01201057
Drug: 1.0% SPL7013 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gel
Trial: NCT01201057
Drug: 3.0% SPL7013 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gel